Trinity Biotech Valuation Multiples

Trinity Biotech Overview

About Trinity Biotech

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Founded

1992

HQ

Employees

401

Website

trinitybiotech.com

Sectors

Medical Devices

Financials (FY)

Revenue: $62M

EBITDA: ($17M)

EV

$124M

Valuation Multiples

Multiples.vc

Start free trial

Trinity Biotech Financials

Trinity Biotech reported last fiscal year revenue of $62M and negative EBITDA of ($17M).

In the same fiscal year, Trinity Biotech generated $21M in gross profit, ($17M) in EBITDA losses, and had net loss of ($32M).

Trinity Biotech P&L

In the most recent fiscal year, Trinity Biotech reported revenue of $62M and EBITDA of ($17M).

Trinity Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

Trinity Biotech Stock Performance

Trinity Biotech has current market cap of $13M, and enterprise value of $124M.

Trinity Biotech's stock price is $0.69.

Trinity Biotech Valuation Multiples

Trinity Biotech trades at 2.0x EV/Revenue multiple, and (7.3x) EV/EBITDA.

Trinity Biotech Financial Valuation Multiples

As of April 5, 2026, Trinity Biotech has market cap of $13M and EV of $124M.

Equity research analysts estimate Trinity Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Trinity Biotech has a P/E ratio of (0.4x).

Trinity Biotech Margins & Growth Rates

Trinity Biotech's revenue in the last fiscal year grew by 8%.

Trinity Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Trinity Biotech Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Trinity Biotech M&A Activity

Trinity Biotech acquired XXX companies to date.

Last acquisition by Trinity Biotech was on XXXXXXXX, XXXXX. Trinity Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Trinity Biotech Investment Activity

Trinity Biotech invested in XXX companies to date.

Trinity Biotech made its latest investment on XXXXXXXX, XXXXX. Trinity Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).